Merck’s Gardasil 9 Receives FDA’s Expanded Label Approval for Prevention of HPV Related Disorders

 Merck’s Gardasil 9 Receives FDA’s Expanded Label Approval for Prevention of HPV Related Disorders

Merck’s Gardasil 9 Receives FDA’s Expanded Label Approval for Prevention of HPV Related Disorders

Shots:

  • The approval is based on a study assessing Gardasil 9 in 13,000 patients (age 27- 45 yrs) for the prevention of certain cancers and diseases caused by the nine HPV types, testing its safety and efficacy
  • In 2006 & 2014, FDA approved Gardasil (for females) & Gardasil 9 (males & females, aged 9 to 26 yrs.) to prevent certain cancers and diseases caused by four (6, 11, 16 & 18) HPV types and additional five (31, 33, 45, 52 & 58) HPV types respectively
  • Gardasil 9 is a vaccine indicated for the prevention of cervical, vulvar, vaginal, and anal cancers caused by HPV in women and prevention of anal cancer in men and also received FDA’s PR designation

Click here to read full press release/ article | Ref: Merck & Co. | Image: The conversion

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post